SOLACI-CACI 2021 | Complex Pulmonary Hypertension and Aortic Endovascular Aneurysm Session

✔️ Watch again the Session on “Complex Pulmonary Hypertension and Aortic Endovascular Aneurysm” in the SOLACI-CACI 2021 Congress.

👨‍🏫 Program:

SESSION I: Chronic Thromboembolic Pulmonary Hypertension

  • 02:48 – Definition, epidemiology, diagnostic algorithm and pharmacological treatment. – Pedro Trujillo
  • 16:27 – Invasive Endovascular Strategies in Chronic PTE: Pulmonary Angioplasty – Fabio Solano
  • 30:13 – Surgical Thromboendarterectomy. Current Indications and Outcomes – Mariano Camporrotondo

👉🏻 Panelists: Damonte, Marcelo – Fernández, Juan – Gottschald, Marcelo – Leite, Marta – Nahin, Marcelo

SESSION II: Aortic Aneurysms

  • 51:50 – Abdominal Aortic Artery: Different Necks, Different Devices: Options Overview – Juan Varela
  • 01:03:37 – Thoracic Aorta. The Subclavian Artery. How Can We Obtain a Correct Proximal Neck? Complete and Incomplete Debranching – Chang Shu
  • 01:15:59 – Type B Dissection in Sub-Acute Stage: When and How to Intervene – Douglas Cavaye

👉🏻 Panelists: Furuya, Luis – Mendaro, Esteban – Michel, David – Razuk, Álvaro
👉🏻 Chairpersons: José Álvarez, Mariano Ferreira & Marco Martínez Ríos
👉🏻 Digital Moderator: Juan Arellano


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...